Johnson & Johnson (JNJ.US) recently announced the latest research results of the phase 3 clinical trial CARTITUDE-4.
The Zhitong Finance App learned that Johnson & Johnson (JNJ.US) recently announced the latest research results of the phase 3 clinical trial CARTITUDE-4. The results showed that in patients with recurrent or refractory multiple myeloma (RRMM) who had received 1 to 3 treatment regimens (including proteasome inhibitors) and were resistant to lenalidomide, a single infusion with Car-T cell therapy Carvykit (cilta-cel), developed in collaboration with Legendary Biology, significantly increased the negative rate of patients for microresidual disease (MRD) compared with standard treatment plans. MRD is an important prognostic indicator for patients with multiple myeloma to prolong survival. Negative MRD means that cancer cells cannot be detected in the blood using sensitive testing methods.
Cilta-cel is a CAR-T cell immunotherapy targeting B-cell maturation antigen (BCMA). BCMA is mainly expressed on the surface of malignant multiple myeloma B cells and plasma cells. Cilta-cel's chimeric antigen receptor protein contains two binding domains for BCMA and is designed to bind with high affinity to human BCMA. After binding to cells expressing BCMA, chimeric antigen receptors can promote T cell activation, proliferation, and target cell clearance. Cilta-cel was initially developed by Legend Biotech. In December 2017, Janssen, a subsidiary of Johnson & Johnson, reached an exclusive global license and cooperation agreement with Legend Biotech to jointly develop and commercialize cilta-cel.
